|
|
|
|
A meta-analysis suggested that in CVST patients who are treated with anticoagulants, the risk of ICH is low, but acknowledge that an impact of up to 9% of new ICH cannot be ruled out. As there is not enough evidence for the safety of anticoagulant therapy in patients with early ICH associated CVST, the therapeutic decision must be individualized and the rebleeding risk should be weighed in those patients. |
|